Previous research found that AhR was overexpressed in thyroid cancer, particularly in BRAFV600E mutant ones, and it participated in thyroid cancer initiation and progression by regulating the establishment of an immunosuppressive tumor microenvironment and the epithelial to mesenchymal transition (Moretti et al., 2020). This evidence concerns the gene AHR and thyroid gland carcinoma.